American Gene Technologies® International Inc. (AGT™) is a private biotechnology company pursuing cures and treatments for infectious diseases, cancers, and monogenic disorders. AGT™'s emerging gene and cell therapeutics programs are designed to: ✅ Create immunotherapy for HIV disease with gene-modified T cells ✅ Activate innate T cell immunity capable of killing all tumor cells with its vector used in immuno-oncology ✅ Treat PKU by bringing a functional gene into cells that express a dysfunctional gene due to mutation ✅ Advance clinically to provide human proof of concept For over a decade, AGT™ has developed, tested, and banked thousands of lentiviral vectors that can be adapted to the specific needs of new target diseases. AGT™ has developed gene therapy for diseases using this rapid gene delivery platform. GENE THERAPIES AGT™’s platform allows it to pursue clinical “cures” for complex diseases. The company has developed patent-protected gene therapeutics that are breakthroughs in medicine. *** See our extensive award winning patents on our website *** HIV/AIDS Immunotherapy for HIV disease with gene-modified T cells IMMUNO-ONCOLOGY Activates innate T cell immunity capable of killing all tumor cells with its vector used in immuno-oncology PHENYLKETONURIA (PKU) Treats PKU by bringing a functional gene into cells that express a dysfunctional gene due to mutation AGT™'s Core Objectives ✔️ Leverage our lentivirus platform to create highly-effective targeted genetic medicines ✔️ Create solutions for patients across a spectrum of infectious diseases, cancers and inherited disorders ✔️ Collaborate with leading medical researchers from around the globe To learn more and get in touch with American Gene Technologies® Inc., contact us today at https://www.americangene.com/contact-us/
View Top Employees from American Gene Technologies® International Inc.Website | http://www.americangene.com/ |
Revenue | $25 million |
Funding | $1.5 million |
Employees | 42 (42 on RocketReach) |
Founded | 2007 |
Address | 9713 Key West Ave 500, Rockville, Maryland 20850, US |
Phone | (301) 337-2100 |
Fax | (301) 337-2101 |
Technologies |
JavaScript,
HTML,
PHP
+53 more
(view full list)
|
Category | Biotechnology Research, Business Services General, Drug Discovery, Lentiviral vector-based gene therapy, Business Services, Biotechnology, HIV and Hepatitis-C Viral Therapeutics, Cancer Therapeutics, Autosomal Disorders |
Web Rank | 7 Million |
Keywords | american gene technologies, jeff galvin, jerry vockley bio, agt treatment protocol, gene-therapy companies |
SIC | 87, 873 |
NAICS | 541, 54171, 54, 5417, 541714 |
Looking for a particular American Gene Technologies® International Inc. employee's phone or email?
The American Gene Technologies® International Inc. annual revenue was $25 million in 2023.
Jeff Boyle is the Chief Science Officer of American Gene Technologies® International Inc..
42 people are employed at American Gene Technologies® International Inc..
American Gene Technologies® International Inc. is based in Rockville, Maryland.
The NAICS codes for American Gene Technologies® International Inc. are [541, 54171, 54, 5417, 541714].
The SIC codes for American Gene Technologies® International Inc. are [87, 873].